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I am writing to correct some misrepresentations of the toxicity of Hexamoll DINCH that were presented by Van Vliet et al. The authors indicate that DINCH causes nephrotoxicity following repeated oral exposure (Table 1 , page 553). This is incorrect. The SCENIHR report clearly indicates the kidney as the critical endpoint (page 44, Table 12 ), but this is based on increased kidney weight not nephrotoxicity (it is noteworthy that SCENIHR was an independent review and did not rely solely on the conclusions of the study authors). The report indicates that relative kidney-to-body weights were increased relative to controls resulting from accumulation of alpha-2-u microglobulin, a ratspecific protein that has no relevance for humans. The authors state that for studies conducted on Hexamoll DINCH, the 'experimental design does not conform to the guidelines of the Organisation of Economic Co-operation and Development (OECD)' (paragraph 2, second column, page 553). This is incorrect. As stated in the SCENIHR report, 'all studies were performed under GLP conditions according to OECD guidelines' (page 81). Indeed, all studies were conducted for submission to regulatory agencies for approval of manufacture and sale, and therefore needed to follow OECD guidelines. The authors state that 'In the multigenerational study, although there was a significant decrease in male anogenital index and anogenital distance in the high-dose group, these were not considered biologically significant by study authors as other parameters like descending testes, testes weight and sperm were not affected' (paragraph 2, second column, page 553). This is misleading and incomplete. The SCENIHR report states that high-dose males and females in a pre-and postnatal developmental toxicity study had lower anogenital index relative to controls. Thus, the effect is not gender-specific and is inconsistent with anti-androgenic properties. This is also stated in the SCENIHR report (page 82), but was omitted by the authors.
It is well understood that there is a pressing need in the market for suitable alternative plasticizers in applications where significant exposures may occur. Hexamoll DINCH has been proven to be an effective plasticizer in many sensitive medical applications. It is important that the correct information be provided to decision makers so that unbiased assessments can be conducted.
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(page 74 in the 2007 report; page 44 in the Table 12 footnote to which Dr David refers, and page 81 in the 2008 report), and unlike alpha-2-u-microglobulin, alpha-2-macroglobulin is a human protease inhibitor. 1, 2 It is possible that this was a mistake by EU SCENIHR. However, it should be noted that the available literature regarding the health effects of DINCH was limited to summaries by BASF and the review in the EU SCENIHR report of unreferenced and unpublished animal studies submitted by BASF.
1,2 The publication of toxicological studies would enable independent evaluation of study results and prevent misinterpretation.
With regards to Dr David's second point regarding the adherence of the BASF studies to the OECD/GLP guidelines, while the 90-day oral toxicity rodent study seems indeed to have been performed under OECD guideline (no. 408), the adherence of the developmental study to OECD guidelines is unclear. In an unpublished but available draft document, BASF states that the pre-postnatal developmental toxicity study in Wistar rats 'was roughly based on (OECD, EPA, EC) guidelines'. 3 Finally, regarding Dr David's last concern about the anogenital index (AGI) result from the pre-and postnatal developmental toxicity study, van Vliet et al. will submit a correction to the journal's editor to request that our online publication reflect that the AGI decrease was present in both genders, not just males. However, if this is the case, it is a very unusual finding and may well be of biologic significance.
We are in full agreement with Dr David that there is an acute need in the market for suitable alternative plasticizers (and PVC-free polymers), especially in high exposure settings. As BASF's DINCH may be 'an effective plasticizer in many sensitive medical applications', it is important that relevant dataFboth industry and publicly fundedFbe openly provided to the public as well as regulators, so that 'unbiased assessments can be conducted'. Allowing access to and independent interpretation of industry-conducted study data is critical in promoting a more transparent, efficient and reliable process of identification of adverse effect levels and general pre-market testing of DEHP-alternatives. 
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